These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30817887)

  • 21. Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa.
    Palanisamy NK; Ferina N; Amirulhusni AN; Mohd-Zain Z; Hussaini J; Ping LJ; Durairaj R
    J Nanobiotechnology; 2014 Jan; 12():2. PubMed ID: 24422704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of Silver Nanoparticles in Overcoming the Intrinsic Resistance of
    Krychowiak-Maśnicka M; Krauze-Baranowska M; Godlewska S; Kaczyński Z; Bielicka-Giełdoń A; Grzegorczyk N; Narajczyk M; Frackowiak JE; Krolicka A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silver nanoparticles: Antimicrobial activity, cytotoxicity, and synergism with N-acetyl cysteine.
    Hamed S; Emara M; Shawky RM; El-Domany RA; Youssef T
    J Basic Microbiol; 2017 Aug; 57(8):659-668. PubMed ID: 28543603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles against resistant Pseudomonas spp.
    Venegas MA; Bollaert MD; Jafari A; Bondoc JMG; Twilley J; Thompson W; Movahedzadeh F
    Microb Pathog; 2018 May; 118():115-117. PubMed ID: 29548697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gum arabic capped-silver nanoparticles inhibit biofilm formation by multi-drug resistant strains of Pseudomonas aeruginosa.
    Ansari MA; Khan HM; Khan AA; Cameotra SS; Saquib Q; Musarrat J
    J Basic Microbiol; 2014 Jul; 54(7):688-99. PubMed ID: 24403133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of Tobramycin by Silver Nanoparticles against Pseudomonas aeruginosa Biofilms.
    Habash MB; Goodyear MC; Park AJ; Surette MD; Vis EC; Harris RJ; Khursigara CM
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine (pytz)-capped silver nanoparticles (TzAgNPs) inhibit biofilm formation of Pseudomonas aeruginosa: a potential approach toward breaking the wall of biofilm through reactive oxygen species (ROS) generation.
    Chakraborty P; Joardar S; Ray S; Biswas P; Maiti D; Tribedi P
    Folia Microbiol (Praha); 2018 Nov; 63(6):763-772. PubMed ID: 29855854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of antibacterial silver nanoclusters to
    Soundy J; Day D
    J Med Microbiol; 2020 Apr; 69(4):640-652. PubMed ID: 32125966
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of nano-silver, nano-copper, deconex and benzalkonium chloride on biofilm formation and expression of transcription regulatory quorum sensing gene (rh1R) in drug-resistance Pseudomonas aeruginosa burn isolates.
    Gholamrezazadeh M; Shakibaie MR; Monirzadeh F; Masoumi S; Hashemizadeh Z
    Burns; 2018 May; 44(3):700-708. PubMed ID: 29290510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-ESBL investigation of chitosan/silver nanocomposites against carbapenem resistant Pseudomonas aeruginosa.
    Rajivgandhi G; Maruthupandy M; Veeramani T; Quero F; Li WJ
    Int J Biol Macromol; 2019 Jul; 132():1221-1234. PubMed ID: 30946905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of antibacterial efficacy of phyto fabricated silver nanoparticles using Mukia scabrella (Musumusukkai) against drug resistance nosocomial gram negative bacterial pathogens.
    Prabakar K; Sivalingam P; Mohamed Rabeek SI; Muthuselvam M; Devarajan N; Arjunan A; Karthick R; Suresh MM; Wembonyama JP
    Colloids Surf B Biointerfaces; 2013 Apr; 104():282-8. PubMed ID: 23334182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa.
    Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H
    Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologically synthesized silver nanoparticles as potent antibacterial effective against multidrug-resistant Pseudomonas aeruginosa.
    Campo-Beleño C; Villamizar-Gallardo RA; López-Jácome LE; González EE; Muñoz-Carranza S; Franco B; Morales-Espinosa R; Coria-Jimenez R; Franco-Cendejas R; Hernández-Durán M; Lara-Martínez R; Jiménez-García LF; Fernández-Presas AM; García-Contreras R
    Lett Appl Microbiol; 2022 Sep; 75(3):680-688. PubMed ID: 35687297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of AMP2041 against human and animal multidrug resistant Pseudomonas aeruginosa clinical isolates.
    Cabassi CS; Sala A; Santospirito D; Alborali GL; Carretto E; Ghibaudo G; Taddei S
    Ann Clin Microbiol Antimicrob; 2017 Mar; 16(1):17. PubMed ID: 28335779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tailoring shape and size of biogenic silver nanoparticles to enhance antimicrobial efficacy against MDR bacteria.
    Kumari M; Pandey S; Giri VP; Bhattacharya A; Shukla R; Mishra A; Nautiyal CS
    Microb Pathog; 2017 Apr; 105():346-355. PubMed ID: 27889528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy.
    Ruiz-Garbajosa P; Cantón R
    Rev Esp Quimioter; 2017 Sep; 30 Suppl 1():8-12. PubMed ID: 28882007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.